• If you are keeping an eye on AbbVie and wondering whether its shares offer good value right now, you are in the right place.
• AbbVie’s stock price has climbed 1.7% in the past week and delivered an impressive 31.7% year-to-date, building on a strong run of 38.2% over the past twelve months.
• Fueling these gains, news of regulatory progress on AbbVie's drug pipeline and notable collaborations in oncology have caught investor attention, further strengthening the company’s outlook. Renewed interest in large-cap pharmaceutical stocks has also played a role, drawing both growth-seeking and risk-conscious investors to the sector.
• Right now, AbbVie scores a 4 out of 6 on our undervaluation checks. We are about to break down what that really means using multiple approaches, and at the end of this article, we will reveal an even smarter way to look at valuation.

Approach 1: AbbVie Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) model estimates a company's intrinsic value by projecting its future cash flows and then discounting those amounts back to their value in today's dollars. This approach helps investors assess whether a stock is currently trading below or above what it is fundamentally worth.

For AbbVie, the DCF analysis starts with the company's current Free Cash Flow, which stands at $19.86 billion. Analyst forecasts predict strong growth, with Free Cash Flow expected to rise steadily in the coming years. By 2029, projections show AbbVie's Free Cash Flow reaching $32.19 billion. The estimates for the following decade continue to climb, but at a slower pace as modeled by Simply Wall St beyond the analyst forecast horizon.

Based on these cash flow projections, the DCF model calculates AbbVie's intrinsic value at $433.65 per share. Compared to the current market price, this suggests AbbVie is trading at a 45.5% discount. According to this model, the stock appears significantly undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests AbbVie is undervalued by 45.5%. Track this in your watchlist or portfolio, or discover 928 more undervalued stocks based on cash flows.

Approach 2: AbbVie Price vs Sales

The Price-to-Sales (P/S) ratio is a popular valuation metric for profitable companies in the biopharmaceutical sector. It helps investors evaluate how much they are paying for each dollar of the company's sales, which is especially relevant for firms like AbbVie that generate substantial and consistent revenues.

Growth expectations and perceived risks play a significant role in what is considered a “normal” or “fair” P/S ratio. Companies with higher growth prospects or lower risks typically command higher P/S multiples, while riskier or slower-growing firms trade at lower ratios.

Currently, AbbVie trades on a 7.0x P/S ratio. For context, this sits above its peer group average of 6.28x, but remains below the biotech industry average of 11.59x. These measurements give a sense of how AbbVie stacks up to its competitors and sector as a whole, but they do not capture every nuance.

This is where Simply Wall St’s proprietary “Fair Ratio” comes into play. The Fair Ratio for AbbVie is calculated at 11.54x, taking into account not just company size and industry, but also earnings growth, profit margins, and unique risk factors. This deeper analysis makes the Fair Ratio a more comprehensive benchmark than a simple peer or industry comparison.

Since AbbVie’s current P/S ratio of 7.0x sits well below its Fair Ratio of 11.54x, this suggests the stock is undervalued on this basis, even considering its current performance and risk profile.

Result: UNDERVALUED

PS ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1432 companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your AbbVie Narrative

Earlier we mentioned that there's an even better way to understand valuation, so let's introduce you to Narratives. A Narrative is a simple yet powerful tool that lets you connect your story or perspective on AbbVie, your expectations for its future revenue growth, earnings, profit margins, and fair value, with the numbers you see in the model.

More than just a set of numbers, a Narrative links the company’s business outlook and developments, such as pipeline expansions or patent challenges, directly to a tailored financial forecast and a resulting fair value estimate. It helps make sense of valuation by showing how your views and assumptions translate into numbers you can actually act on.

Available and easy to use on Simply Wall St’s Community page, Narratives are used by millions of investors to test their thinking and compare views. By contrasting your own calculation of fair value with the current price, Narratives help guide your buy or sell decisions with greater clarity and confidence.

Unlike static models, Narratives are updated dynamically whenever new information, like fresh earnings, drug approvals, or breaking news, enters the picture, so your perspective stays current as AbbVie evolves.

For example, one investor’s bullish Narrative for AbbVie might be anchored in aggressive revenue growth and profit margin expansion tied to pipeline success and international launches, leading to a high fair value of $255. In contrast, a more cautious view focused on risk from patent expiries or regulatory headwinds yields a fair value closer to $170.

Do you think there's more to the story for AbbVie? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.